1.
Bioorg Med Chem Lett
; 13(22): 3983-7, 2003 Nov 17.
Article
in English
| MEDLINE
| ID: mdl-14592490
ABSTRACT
Aryldihydropyridazinones and aryldimethylpyrazolones with 2-benzyl vinylogous amide substituents have been identified as potent PDE3B subtype selective inhibitors. Dihydropyridazinone 8a (PDE3B IC(50)=0.19 nM, 3A IC(50)=1.3 nM) was selected for in vivo evaluation of lipolysis induction, metabolic rate increase, and cardiovascular effects.